Oncology Medical News about chemoradiotherapy, esophageal cancer

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

A randomized phase II study of cisplatin/5-FU concurrent chemoradiotherapy for esophageal cancer: Short-term infusion vs protracted infusion chemotherapy (KROSG0101/JROSG021)
Radiotherapy and Oncology, 08/06/09

Nishimura Y et al. - In a trial to compare the toxicity and efficacy of combining short-term chemotherapy (CT) or protracted CT with radiotherapy (RT) for esophageal cancer, it was concluded that protracted infusion CT with RT provides no advantage over standard short-term infusion CT with RT for esophageal cancer.

Methods

Eligible pts were <75 yrs and with performance status (PS) of 0–2, and had stages II–IVA esophageal cancer.
2 cycles of cisplatin 70 mg/m2 for 1 day and 5-FU 700 mg/m2 for 5 days (arm A) or cisplatin 7 mg/m2 for 10 days and 5-FU 250 mg/m2 for 14 days (arm B) were given with RT of 60 Gy/30 fractions/7 wks (1-wk split).

Results

Of 91 pts enrolled, 46 were randomized to arm A and 45 to arm B.
2 cycles of CT were given concurrently with RT for 89% in arm A and for 71% in arm B with significant difference.
2- and 5-yr overall survival rates for arm A were 46% and 35%, while those for arm B were 44% and 24%, respectively, without significant difference.
2- and 5-yr progression-free survival rates for arm A were 30% and 30%, while those for arm B were 29% and 12%, respectively.

<< Previous
Modafinil for attentional and psychomotor dysfunction in advanced...

Next >>
Overexpression of X-linked inhibitor of apoptosis protein (XIAP)...